[HTML][HTML] Immunotherapy for hepatocellular carcinoma: current limits and prospects
C Zhong, Y Li, J Yang, S Jin, G Chen, D Li, X Fan… - Frontiers in …, 2021 - frontiersin.org
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
C Zhong, Y Li, J Yang, S Jin, G Chen… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects.
C Zhong, Y Li, J Yang, S Jin, G Chen, D Li… - Frontiers in …, 2021 - europepmc.org
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
C Zhong, Y Li, J Yang, S Jin, G Chen, D Li… - Immunotherapy in …, 2021 - books.google.com
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects Page 112 REVIEW
published: 29 March 2021 doi: 10.3389/fonc. 2021.589680 Immunotherapy for Hepatocellular …
published: 29 March 2021 doi: 10.3389/fonc. 2021.589680 Immunotherapy for Hepatocellular …
[HTML][HTML] Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
C Zhong, Y Li, J Yang, S Jin, G Chen, D Li… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects.
C Zhong, Y Li, J Yang, S Jin, G Chen, D Li… - Frontiers in …, 2021 - europepmc.org
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
C Zhong, Y Li, J Yang, S Jin, G Chen… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …